Fig 1.
Participants’ timeline.
Table 1.
Prevalence of O. volvulus, M. perstans and Loa loa infections in the study area.
Fig 2.
M. perstans, O. volvulus- and/or Loa loa-infected participants and non-helminth-infected endemic controls will be enrolled in this study and grouped according to their BMI as lean (BMI<25), overweight (BMI 25–29) or obese individuals (BMI≥30). M. perstans and O. volvulus positive participants will receive 200 mg doxycycline for 42 days. All participants will receive 400 mg of albendazole every three months to treat intestinal helminth infections. Before, 12 month and 18 months after doxycycline treatment, anthropomorphic, metabolic and immunological measurements will be performed as indicated in the figure.
Table 2.
Inclusion and exclusion criteria.
Table 3.
Trial variables and predicted outcomes.